CLINICAL_TRIALS
trial_result
· 2017-07-28
Clinical Trial Update: A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy [Phase 3]
Summary
Phase 3 trial of nusinersen (ISIS 396443) in infants with spinal muscular atrophy was terminated; results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 3 | Status: TERMINATED | Results posted: 2017-07-28